预约演示
China NMPA accepts Astellas’ sBLA for urothelial cancer treatment
2024-03-29
临床结果临床3期上市批准抗体药物偶联物
Astellas Pharma’s enfortumab vedotin is a Nectin-4- targeted antibody-drug conjugate. Credit: BalkansCat / Shutterstock.com.
Astellas PharmaDruenfortumab vedotin of thNectin-4National Medical Products Administration (NMPA) has accepted Astellas Pharma’s supplemental biologics license application (sBLA) for enfortumab vedotin plus KEYTRUDA (pembrolizumab) for urothelial cancer.
This combination therapy is aimed at treating adult patients with previously untreated locally advanced or metaAstellas Pharmaal cancer (la/mUC).enfortumab vedotinKEYTRUDApembrolizumaburothelial cancer
Enfortumab vedotin is a targeted antibody-drug conjugate (ADC) directed against the Neclocally advanced or metastatic urothelial cancer (la/mUC)
Enfortumabivedotinoval for the combination regimen could revolutionise the standard Nectin-4 proteint-line la/mUC, offering an alternative to the platinum-containing chemotherapy that is currently administered.
The sBLA is based on the data from the randomised, open-label, controlled Phase III EV-302 clinical trial, also known as KEYNOTE-A39.
See Also:EV-302
Arvinas gets grant for treatment of prostate cancer with specific compounds
Arvinasun Dang Pharmaceutical gets gprostate cancerable composition of testosterone undecanoate for testosterone deficiency treatment
This study compared enfortumab vedotin in combination with pembrolizumab to platinum-containing chemotherapy in 886 patients.
Chong Kun Dang Pharmaceuticalgression-free survival (PFS) were the triatestosterone undecanoatetestosterone deficiency
Secondary endpoints included objective response rate (ORR), duration of response (DOR), and safety profiles.
The results demonstrenfortumab vedotinination of enfortumabpembrolizumab pembrolizumab significantly improved OS and PFS, with meaningful clinical outcomes when compared to the standard chemotherapy regimen.
The safety profile of the combination therapy was in line with prior reports without any new safety concerns identified.
In addition to the CDE’s review, the NMPA is considering enfortumab vedotin as a treatment option for la/mUC patients who have previously undergone therapy with a PD-1/L1 inhibitor and platinum-based chemotherapy.
Parallelly, the European Medicines Agency’s Commienfortumab vedotin Produpembrolizumab Use (CHMP) and Japan’s Ministry of Health, Labour and Welfare (MHLW) are also reviewing the combination regimen.
In December last year, the US Food and Drug Administration granted approval for this combination therapy.
Astellas Oncology Development head and senior vice-presidenfortumab vedotinh said: “Locally advanced or metastatic urothelial cancer is a life-threatening conditioPD-1/L1 inhibitorPD-1/L1ina with nearly half of those diagnosed succumbing to the disease.
“The CDE’s accepEuropean Medicines Agencyortumab vedotin and pembrolizumab brings us one step closer to delivering a much-needed, innovative new treatment option for this patient population.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。